A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jul 2024 Last checked against ClinicalTrials.gov record.
26 Mar 2019 According to the CSL Behring media release, based on the data from the PATH and PRIMA trials, Japan's Ministry of Health, Labour and Welfare has approved Privigen [human normal immunoglobulin, 10% liquid, intravenous], ready-to-use therapy for acute and maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
05 Jul 2018 According to a CSL Behring media release,data from this trial will be presented at 15th International Congress on Neuromuscular Diseases (ICNMD).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com